The global perennial allergic rhinitis drug market is anticipated to grow at a significant CAGR of 4.0% during the forecast period 2022-2028. The increased awareness of allergic responses around the globe is likely to fuel the growth of the perennial allergic rhinitis market. Additionally, the high quality of drugs and nasal sprays supplied by manufacturers for the treatment of chronic allergic rhinitis is predicted to fuel the growth of the market.
Browse the full report of " Global Perennial Allergic Rhinitis Drug Market Size, Share, and Trends Analysis Report By Type (Antihistamines, Asapiprant, APC-3000, Bilastine, and Others) and By Application (Hospitals, Clinics, and Others) Forecast 2022-2028" at https://www.omrglobal.com/industry-reports/perennial-allergic-rhinitis-drug-market
For instance, in October 2021, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. signed a agreement with Marinomed Biotech AG, whereby the company would gain the rights for the development, manufacture, and commercialization of Budesolv in China which is an indicated for allergic rhinitis. The signing of the license agreement will further expand the company’s product line and enhance Luoxin's competitive edge in the area of respiratory diseases. Further, in September 2021, Hikma Pharmaceuticals PLC announced the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second-generation antihistamine molecule for the treatment of allergic rhinitis and urticaria.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - including, GlaxoSmithKline PLC, Sanofi SA, Merck & Co. inc., Pfizer Inc., Novartis International AG, among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Perennial Allergic Rhinitis Drug Market Report Segment
By Type
By Application
Global Perennial Allergic Rhinitis Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World